


Follow *The* **MONEY**

2019

CANNABIS REPORT

How To Profit From The Global Cannabis Boom

Updated Version




'IN THIS BRIEF REPORT, I WANT TO INTRODUCE YOU TO WHAT I HAVE LEARNED ABOUT INVESTING IN THIS NEW AND GROWING MARKET INCLUDING THE EVOLVING LEGAL STATUS OF THIS CONTROVERSIAL PLANT, THE EXPECTED LONG-TERM GROWTH PROSPECTS, AND HOW TO IDENTIFY HIGH-QUALITY CANNABIS STOCKS ON YOUR OWN.'

One of the best opportunities that I have uncovered in recent years is in the growing global cannabis market.

Welcome to the exciting world of global cannabis investing!

My name is Jerry Robinson and I have been investing in stocks since the mid-1990s. As the founder of FollowtheMoney.com, I share my investing and trading wisdom gained over the past two decades with our members and seek to alert them to new and potentially profitable investment and trading opportunities. One of the best opportunities that I have uncovered in recent years is in the growing global cannabis market.



In this brief report, I want to introduce you to what I have learned about investing in this new and growing market including the evolving legal status of this controversial plant, the expected long-term growth prospects, and how to identify high-quality cannabis stocks on your own. I will conclude by sharing seven cannabis stocks that I personally own for the "long-term" and that I expect to provide outsized returns well into the future. I will also share five other stocks that I do not currently own, but that I also expect to perform exceptionally well as the cannabis industry matures in the coming years.

Enjoy the report and happy investing to you!

Jerry Robinson

A Brief History of Cannabis

The cannabis plant, which likely originated in Central Asia, has been used for millennia for its industrial, medicinal, and recreational value.

The **industrial** applications for cannabis have largely been for the hemp fiber that is processed from the non-psychoactive stalk (or stem) of a certain variety of the cannabis sativa plant. (While marijuana and hemp are technically derived from different varieties of the cannabis plant, they are similar in the same way that lemons and limes are both considered citrus fruits.)

Hemp fiber, which contains miniscule amounts of the psychoactive THC that create the feeling of being "high," has been used to create rope, paper, clothing, as well as foodstuffs, such as hemp milk and hemp oil, for thousands of years.

In America, for example, the Puritans, and even George Washington himself, were hemp farmers. Hemp was used extensively as a maritime fiber due to its extreme durability and easy cultivation. (Ironically, the sails and lines on the Mayflower ship were composed of hemp. I say "ironically" because hemp was outlawed by Washington D.C. in 1937 and was only officially made fully legal again in 2018.)

The **medical** applications for cannabis also have a rich history with the plant being used for pain relief. In addition to being one of the 50 "fundamental" herbs in traditional Chinese medicine, usage of cannabis for medical purposes was popular for both humans and animals in ancient Israel, India, Greece, Egypt, and many other cultures.

Finally, the **recreational** applications of cannabis also span thousands of years. The drug has been used to inspire creativity, increase sexual drive, invoke euphoria, and served as a tool in religious rituals and ceremonies.

The Evolving Legal Status of Cannabis

While cannabis has been legal for most of human history, it was only in the last century that this unique plant was banned from public consumption through stiff regulations by heavy-handed governments, who have cited "health safety" and "moral concerns" as their primary reasons for banning the substance.

The U.S. federal government's cannabis crackdown began in the 1930s after recreational use of the plant became largely associated with Mexican immigrants. The **Federal Marihuana Act of 1937** (*note the Spanish spelling of the word "marijuana," which served its xenophobic purpose at the time*) effectively banned cannabis for public consumption but the penalties for possession did not become significant until the 1950s.

Finally, by the 1980s, cannabis became regulated under the **Controlled Substance Act**, which listed the plant as a *Schedule I* drug. As such, the Federal government had effectively relegated the plant to the same status as heroin and cocaine, deeming it highly addictive with no medicinal uses. The Schedule I classification has also largely prevented broad scientific research into cannabis.

Schedule	Description	Examples
Schedule I	Drugs with the highest potential for abuse and no currently accepted medical use in U.S.	Heroin, LSD, Marijuana
Schedule II	Drugs with a high potential for abuse but with current accepted medical use in U.S.	Crystal Meth, PCP, Cocaine, Oxycodone
Schedule III	Drugs with moderate to low abuse potential but with current accepted medical use in U.S.	Anabolic Steroids, Ketamine, Testosterone, Codeine
Schedule IV	Drugs with low abuse potential than Schedule III drugs but with current accepted medical use in U.S.	Valium, Xanax, Darvon, Soma, Ambien
Schedule V	Drugs with less abuse potential than Schedule IV drugs but with current accepted medical use in U.S.	Cough medicines with codeine (Robitussin AC)

Since the dawn of the 21st century, however, the legal status of cannabis has been softening across the country as numerous states have decriminalized and/or legalized the plant. While most of these states have been driven by the added revenue provided by legal cannabis sales, they have also been motivated by several promising new scientific studies that have recognized the potential medicinal benefits of the plant. One such study, released in January 2017 by the National Academies of Sciences, Engineering, and Medicine, reviewed more than 10,000 scientific abstracts published since 1999. The **resulting 395-page report** "*found evidence to*

'TEN STATES AND WASHINGTON, DC, HAVE NOW LEGALIZED MARIJUANA FOR RECREATIONAL USE FOR ADULTS OVER 21. MEANWHILE, 33 STATES HAVE LEGALIZED MEDICAL MARIJUANA.'

support that patients who were treated with cannabis or cannabinoids were more likely to experience a significant reduction in pain symptoms. For adults with multiple sclerosis-related muscle spasms, there was substantial evidence that short-term use of certain “oral cannabinoids” – man-made, cannabinoid-based medications that are orally ingested – improved their reported symptoms. Furthermore, in adults with chemotherapy-induced nausea and vomiting, there was conclusive evidence that certain oral cannabinoids were effective in preventing and treating those ailments.”

THC vs CBD

While there are many components that make up (and are produced by) the cannabis plant, there are two major components immediately noteworthy for investors.

Tetrahydrocannabinol (THC)

The psychoactive component that makes you feel ‘high’ is a cannabinoid called THC. While there are some key medical benefits from THC, there are even more in the second major component, CBD.

Cannabidiol (CBD)

The other key component in cannabis is known as CBD, or cannabidiol, which is non-psychoactive. In other words, CBD doesn’t get you “high” but it does boast numerous potential health applications. Consider this table below for some of the potential health effects derived from several cannabinoids, including THC and CBD.

	THC	THC-A	THC-V	CBN	CBD	CBD-A	CBC	CBC-A	CBG	CBG-A	
Pain relief											Analgesis
Reduces inflammation											Anti-inflammatory
Supresses appetite											Anoretic
Stimulates appetite											Appetite stimulant
Reduces vomiting and nausea											Antimetic
Reduces contractions of small intestine											Intestinal antiprokinetic
Relieves anxiety											Anxiolytic
Tranquilizing / psychosis management											Antipsychotic
Reduces seizures and convulsions											Antiepileptic
Suppresses muscle spasms											Antipasmodic
Aides sleep											Anti-insomnia
Treats autoimmune disorders											Immunosuppressive
Reduces blood sugar levels											Anti-diabetic
Prevents nervous system degeneration											Neuroprotective
Treats psoriasis											Antipsioratic
Reduces risk of artery blockage											Anti-ischemic
Kills or slows bacteria growth											Anti-bacterial
Treats fungal infection											Anti-fungal
Inhibits cell growth in tumors / cancer											Anti-proliferative
Promotes bone growth											Bone-stimulant

Source: Emerald Health Therapeutics



Since 2014, Washington has defined hemp as *cannabis sativa* with **less than 0.3% THC** and eliminated restrictions for the sale of hemp-derived products across state lines. However, with the passage of the 2018 Farm Bill, the Congress fully legalized hemp. With CBD (a hemp derivative) **now currently legal in all 50 states**, demand for this non-psychoactive component is *just beginning* to catch fire across the country. According to one research firm, the current market size for CBD in the U.S. is just over \$500 million. That same research firm projects that demand for CBD **could explode** over the next few years with the total market size potentially reaching nearly **\$22 billion by 2022**. That kind of explosive growth potential is obviously attracting savvy investors who want their share of the pie before the institutional investor herd arrives.

Demand for CBD could explode over the next few years with the total market size potentially reaching nearly \$22 billion by 2022.

'ACCORDING TO BMO RESEARCH AND DELOITTE, TOTAL GLOBAL MEDICAL AND RECREATIONAL CANNABIS USE COULD TOP \$200 BILLION. MUCH OF THIS GROWTH IS EXPECTED TO COME AS LEGAL CANNABIS DISRUPTS THE BEVERAGE, TOBACCO, AND THE BIG PHARMA INDUSTRIES, TO NAME A FEW.'

Explosive Growth Potential Straight Ahead

The slow but sure regulatory thaw around cannabis has come amid growing social acceptance of the plant's medicinal benefits. While it is impossible to accurately estimate the total size of the existing black market for marijuana in the United States, most analysts estimate it to be worth around **\$40 billion** (as of 2017). Compare that to the total market cap of the *legal* cannabis industry, which currently sits near **\$11 billion**. Therefore, it is expected that, as the Federal ban on cannabis is finally lifted across the country, the total market cap for the legal cannabis industry could realistically grow **fivefold**, to between **\$40-\$50 billion!** Another 2017 report issued by a leading research firm estimates that the global market for medical cannabis alone could be worth **\$55 billion by 2025**. (*Grand View Research, January 2017*) By getting into the leading companies now, you can position yourself for potentially massive profits as the market grows.

However, there are several reasons why we believe that the size of the U.S. cannabis market could grow much larger than even those estimates upon full U.S. legalization. These include:

1. **Legal fears/Social stigmas.** Many potential U.S. cannabis users living in states where the plant is still illegal largely avoid it out of fear of embarrassing police encounters, massive fines, and even harsh prison sentences. When the plant is finally legal across the U.S., we expect that many first-time users will try cannabis and become semi-regular to regular consumers.
2. **New Methods of Ingestion.** The current black market is mostly composed of dry cannabis herb designed to be smoked or vaped simply to get "high." However, as cannabis becomes increasingly commercialized, new applications like THC-infused and CBD-infused beverages, edibles, and oils promise to open up the market to a whole new generation of non-smoking consumers who may have never otherwise tried cannabis.
3. **Big pharma market share competition.** In addition to the current recreational market, vast new medical applications for cannabis could lead to explosive future growth. This is especially true due to the *non-lethal* pain-relieving power of cannabis, as opposed to the deadly narcotic painkillers that are presently laying waste to Americans simply seeking the same pain relief that cannabis offers.

The opportunity becomes even more compelling when **global growth estimates** are considered. According to BMO Research and Deloitte, total global medical and recreational cannabis use could top **\$200 billion**. Much of this growth is expected to come as legal cannabis disrupts the beverage, tobacco, and the big pharma industries, to name a few.

Institutional Inflows Have Yet To Arrive

Since issuing our first annual Cannabis Investment Report in February 2018, we have seen the cannabis industry as a literal "Green Gold Rush." What we particularly like is that there is, at present, relatively little brand awareness, let alone brand loyalty. This industry has yet to blossom. A flurry of corporate interest and activity in the leading cannabis stocks is expected the day that Washington inevitably provides more evidence of its intentions toward cannabis as a Schedule I drug. It is rare that retail investors are given such a head start to participate in a burgeoning new industry of the U.S. economy -- while it is **still in its infancy**.



For these reasons, we believe **now** may be the perfect time to begin gaining exposure to this industry **before** the big institutional investors arrive, flush with cash, in the wake of full legalization. Finally, the biggest M&A deals are likely still ahead as massive Fortune 500 brands will likely step in after full legalization to buy and build new profitable product lines. The potential opportunities in this space appear staggering -- **if** Washington actually deschedules cannabis.

Canada's Headstart

While the U.S. cannabis market is among the most promising, the growing cannabis market in Canada has a big head start with nationwide legalization occurring in October 2018. While many U.S. states have already decriminalized or legalized cannabis, Washington still stands in the way of future research and commerce due to its punitive Federal prohibition of the plant. Until cannabis is legalized at the Federal level in the U.S., we expect Canada to enjoy the upper hand in this booming new industry. With the legal status regarding cannabis now settled in Canada, Canadian cannabis companies will be able to drive innovations in the industry even as U.S. cannabis firms struggle under punitive laws concocted in Washington. For this reason, we expect Canadian firms to initially enjoy the early fruits of this new industry, both in their own home country and in the U.S., as they build out their infrastructure unencumbered by the obstacles faced by their American peers. However, it is also important to remember that the Canadian economy is nearly ten times smaller than the U.S. economy. So while Canadian companies have indeed beat the U.S. to the punch, plenty of upside potential remains for American companies once the Federal government finally deschedules cannabis.

While the U.S. cannabis market is among the most promising, the growing cannabis market in Canada has a big head start with nationwide legalization occurring in October 2018.




How to Identify High Quality Cannabis Stocks

1. The **experience** of the management team is crucial. Do they have executives who have experience **in the types of markets** that the company is targeting?
2. Corporate management should have a **solid network** to help the company leverage opportunities in vertical and horizontal markets as the cannabis space grows and matures.
3. We prefer to see **solid insider ownership** of shares by top executives, without a lot of insider selling. In fact, watch out for companies that have excessive or unusual amounts of insider selling as that could be a red flag. If management doesn't believe enough in the stock to own it, should you?
4. **Share structure** is vital to consider. If the company issues many warrants or options that could be exercised at a low price, that is also a potential problem. Many companies will inevitably dilute shares by future issuances, but I have found that knowing the potential of this **in advance**, by digging, is very helpful when analyzing cannabis companies.

Ultimately, investors have a few different types of cannabis-related companies to invest in, based upon their specific aims and goals. For example, some companies produce a full-line of both THC and CBD-infused products, while some specialize in one type or the other. Some companies focus on medical applications while others target the recreational market. Additionally, some companies operate at the periphery of the cannabis industry and never “touch the leaf,” which means they face much less regulatory scrutiny and potential legal hurdles.

Some companies operate at the periphery of the cannabis industry and never “touch the leaf,” which means they face much less regulatory scrutiny and potential



2019

7 CANNABIS STOCKS

Poised To Outperform In 2019 And Beyond

#1 - Cronos Group (NSDQ: CRON)

Current Price (as of 1/21/19): \$14.90



Position Trend: ↑

Long-Term Trend: ↑

When considering an investment in the cannabis industry, it's important to think about the potential heavyweight companies in related industries that could move into and easily dominate the space. One such company is U.S. tobacco giant, Altria. Altria has decades of experience navigating, marketing, and selling within a highly regulated market and it also has deep pockets, a massive distribution chain, and a vast political and corporate network. Therefore, when I learned that Altria was investing nearly \$2 billion to take a 45% stake in the Cronos Group (CRON), a leading Canadian cannabis firm, I was intrigued. After all, the executives at Altria had plenty of existing cannabis firms to choose from when seeking a deal in this growing industry. Additionally, Altria also has the right to take another 10% stake in CRON sometime in the future, which would give them majority control. The fact that one of the world's largest and most established cigarette brands chose Cronos to gain an early foothold in this burgeoning industry speaks volumes and suggests that CRON is likely to be a leading cannabis company for years to come. Armed with \$1.8B in cash — as well as advice and know-how from Altria — CRON stands ready to seize upon many new opportunities in 2019 and beyond. We expect that when cannabis is fully legalized in the U.S., CRON will have a major head start in profiting from U.S. consumer demand both from its massive cash pile and its access to Altria's top executives. Aside from the new partnership with Altria, CRON already has a highly successful operation with its portfolio of owned and JV brands spanning four continents. The future looks bright for the Cronos Group as we head into 2019 and beyond.

#2 - Aurora Cannabis (NYSE: ACB)


Current Price (as of 1/21/19): \$6.44

Position Trend: Long-Term Trend: 

Aurora Cannabis (ACB) is a Canadian-based cannabis producer that has built its brand into a household name in the global cannabis space. The company is led by a solid management team that has deep experience in highly regulated industries, including the cannabis space. Through a clever (and ongoing) acquisition strategy, Aurora has been able to gain a global foothold with their operations now spanning 5 continents and 20+ countries including Germany, where Aurora's Pedanios GmbH brand serves as the largest cannabis distributor in the European Union. The company also has established impressive market share in Latin America, with exposure to Uruguay, Colombia, and Mexico. Since August 2016, the company has made 15 strategic acquisitions that have served to boost the company's capabilities and expertise enabling it to exploit the evolving cannabis market through its established and growing distribution channels. Rumors of potential collaboration with Coca-Cola for the production of cannabis-infused drinks sent Aurora's stock price soaring last September but there has been little news since. In January 2018, after a hostile takeover bid, Aurora succeeded in acquiring Cannimed Therapeutics, a leading medical cannabis producer. Then, in May of that same year, Aurora announced it would acquire Medreleaf, another rising and high growth medical cannabis company. Additionally, Aurora has targeted Australia by recently taking a 22.9% stake in Cann Group, which is the first Australian company licensed to cultivate medical cannabis. Along with its impressive history of strategic acquisitions and its growing global footprint, we also like Aurora for many other reasons. These include its aggressive commitment to expanding production capacity to meet rapidly growing global demand as well as its high margin strategy, which seeks to keep its total production costs well below \$1 per gram over the long-term. Aurora's 11 high-tech grow facilities are fully-automated and ready for scale, making the company a compelling investment for those who are looking to seize upon the inevitable growth in the global cannabis market. At full capacity, Aurora's network of facilities will be capable of producing in excess of 500,000 kg per year of high-grade cannabis.

#3 - Canopy Growth (NYSE: CGC)


Current Price (as of 1/21/19): \$43.52

Position Trend: Long-Term Trend: 

Canopy Growth is one of the three largest cannabis manufacturers in the world, based on market-cap, boasting operations in 12 countries across 5 continents. (The two other leaders by market-cap include Aurora Cannabis and Tilray.) As a leading diversified cannabis company, Canopy Growth operates 10 high-tech production facilities from its home base in Canada. In 2018, the company scored a major endorsement through a \$5 billion investment from Constellation Brands (STZ), one of the world's largest liquor companies. This massive cash infusion will undoubtedly be used to help Canopy Growth secure even more market share in the booming cannabis industry through international expansion, and will help them finance future acquisitions of their strongest up-and-coming competitors. Through its large line of leading brands, Canopy Growth is seeking to disrupt several markets including alcohol, sleep aids, pain relief, animal health, and even sports drinks. Its two leading brands include Tweed (retail) and Spectrum (medical), which the company owns outright. Its products take the form of dried flower, oils and concentrates, soft-gel capsules, and hemp. The company has been a prime mover in staking out intellectual property throughout the cannabis space with more than 120 patent applications currently pending, and more in the pipeline. Canopy also boasts an enviable management team co-led by Bruce Linton and Mark Zekulin, two executives who came to the company with impressive track records.

#4 - Charlotte's Web (OTC: CWBHF)

Current Price (as of 1/21/19): \$13.04




Position Trend: 📈

Long-Term Trend: 📈

Formerly known as Stanley Brothers Holdings (named after the seven Stanley brothers: Joel, Jesse, Jon, Jordan, Jared, Josh and Austin Stanley), Charlotte's Web Holdings cultivates, manufactures and distributes a full-line of its proprietary hemp-based cannabidiol (CBD) products in its own FDA-registered labs and sells them through 3,000 retail locations nationwide. As the world's largest CBD producer, their product line includes: CBD oil, CBD capsules, hemp-infused creams and balms, as well as CBD oil for dogs. The company was founded in 2013 and is named after Charlotte Figi, a young epileptic suffering from Dravet syndrome, whose parents found relief for their daughter through the company's concoction of CBD oil. Since its IPO in August 2018, this leading Boulder-based CBD producer has caught the attention of many savvy investors as it seeks to help patients, both young and old, suffering from a wide variety of illnesses. We like Charlotte's Web, in particular, for its established brand and market dominance in the CBD space. The company has enjoyed solid financial growth under the direction of an experienced management team that has proven its ability to continually innovate as this explosive market expands.

#5 - Emerald Health (OTC: EMHTF)

Current Price (as of 1/21/19): \$2.04




Position Trend: ↓

Long-Term Trend: ↓

Emerald Health is a licensed Canadian producer of dried cannabis and cannabis oil for medical and recreational purposes. This vertically-integrated seed-to-sale cannabis firm, based in British Columbia, is led by Executive Chairman Avtar Dhillon, MD, who has spent more than 35 years “building public companies through M&A, establishing dominant IP portfolios, and leading innovative scientific and farming enterprises.” While Emerald Health boasts solid expertise in the cannabis space, they are specifically targeting the medical cannabis market and seek to build powerhouse brands that result in customer loyalty and strong revenue growth over time. The company has also developed an interesting strategy creating brand awareness outside of the traditional cannabis market by selling a full-line of cannabis-free health supplements that support the optimal functioning of the endocannabinoid system, which are sold in drug stores and grocery stores, like Whole Foods, across the U.S. and Canada. In an industry where brand recognition and awareness is key to long-term growth, this strategy has the ability to introduce and capture a large number of future cannabis users by creating goodwill around its line of non-cannabis consumer health products.

#6 - KushCo Holdings (OTC: KSHB)

Current Price (as of 1/21/19): \$5.43




Position Trend: ↑

Long-Term Trend: ↑

KushCo Holdings is a California-based firm that serves as a unique play on the cannabis market, as it specializes in creating products and services related to this burgeoning new industry while never actually touching the cannabis plant. Since being founded in 2010 by a group of young entrepreneurs seeking to revolutionize the cannabis packaging industry, KushCo has become one of the largest distributors of vaporizer products, packaging, supplies, and accessories in the space. One example includes the 60+ different refillable cartridges for vape pens, which KushCo makes or resells, providing it with solid and growing recurring revenue. According to its website, the company has “sold more than 1 billion units and regularly services more than 5,000 legally operated medical and adult-use dispensaries, growers, and producers across North America, South America, and Europe. As the needs of cannabis companies grow in the wake of legalization, KushCo seeks to provide the solutions. Staffed with an in-house legal department with deep cannabis expertise, KushCo envisions being a one-stop shop for cannabis companies of all stripes, whether growers, processors, brand owners, distributors, or dispensaries, all of whom need KushCo’s services, like their compliant labeling and child-proof packaging which often varies, based upon each state or country’s evolving regulatory demands. As one Wall Street analyst (Canaccord Genuity) puts it: “We view KSHB as a pick-and-shovel play on the rapidly growing U.S. legal cannabis industry. By supplying packaging, labels and vape hardware, KSHB does not touch the plant, and the company is delivering strong top-line growth irrespective of which multi-state operators (MSOs) and branded consumer products win.” With sales of recreational and medical cannabis set to explode in the coming years, KushCo has positioned itself well to exploit the inevitable growth that will come.

#7 - Origin House (OTC: ORHOF)

Current Price (as of 1/21/19): \$6.05

Position Trend: Long-Term Trend: 

As the U.S. cannabis market ramps up, certain brands are going to dominate. This is the case in virtually any market. Consider the alcohol industry, for example. If you walk into a liquor store to buy a bottle of red wine, you will immediately notice an enormous variety of brands that could easily paralyze a newcomer. The same is true of liquor, like vodka or whiskey. Certain brands inevitably rise to the top in the mind of consumers, which gives those brands pricing power that is not enjoyed by smaller and lesser known brands. Wine lovers are brand loyal and will continue buying the same brand of wine for years and years. This same brand loyalty is currently being built in the cannabis space. When cannabis users enter a dispensary for the first time, they are largely dependent upon the “budtender” to point them in the right direction. After all, different cannabis strains provide users with different effects. Very few wine drinkers are wine “experts.” They just like certain wines based on taste and even packaging. Those brands who make their mark early in the cannabis space could enjoy the massive benefits that come with a powerhouse brand for years to come. And so will the investors who invest in the brands early. Enter Origin House, which is a California-based cannabis company that invests in, and cultivates, the finest California-based cannabis brands they can find. The thinking behind Origin House’s business model is fairly straightforward as the state of California has always been a trend-setter for the United States. Most trends and fashions that succeed in California inevitably spread throughout the country over time. Origin House seeks to identify the best up and coming California-based cannabis brands and takes a stake in these brands, in order to profit from their potential expansion. It’s a simple business model that even I can understand. As such, we like Origin House and view it as a unique way to earn “angel investor” profits from the rise of the top California brands in the cannabis space over time

Our Top 7 Cannabis Stock Holdings

Ranked by Smartscore

Company	Ticker	Price	Smartscore Rank
Cronos Group	CRON	\$14.90	1
Aurora Cannabis	ACB	\$6.44	2
Canopy Growth	CGC	\$43.52	3
Charlotte's Web	CWBHF	\$13.04	4
Emerald Health	EMHTF	\$2.04	5
KushCo	KSHB	\$5.43	6
Origin House	ORHOF	\$6.05	7

Five More Stocks To Consider

Constellation Brands (STZ)

Medicine Men (MMNFF)

Shopify (SHOP)

Hexo Corp (HYYDF)

Organigram (OGRMF)



Follow The **MONEY**

FIERCE TRUTH • REAL PROFIT



P.O. BOX 1911

FAYETTEVILLE, AR 72702

800-609-5530

//followthemoney.com



About Followthemoney.com

FollowtheMoney.com is a fiercely independent investment research firm led by Christian economist, investor, and best-selling author, Jerry Robinson. Our nationwide team of financial experts boast a combined 203 years of experience in the financial markets.

Since 2010, more than one million FollowtheMoney.com readers and premium members from around the globe have enjoyed our profitable and cutting-edge investing insights.

We trade based on trends, not opinions. Market opinion and sales hype are a dime a dozen and can quickly lead investors to the poorhouse. Instead of relying on opinion, we follow trends.

We stay on the right side of the trend. When the trend begins to rise, we get in. When the uptrend ends, we sell. *(We also provide our premium members with actionable strategies for profiting in a downtrend.)*

Our premium members receive real-time actionable ideas and strategies designed to exploit both short-term and long-term trends.

IMPORTANT DISCLAIMER:

FOLLOW THE MONEY'S SMARTSCORE RATINGS, CHARTS, AND COMMENTARY ARE PROVIDED SOLELY FOR INFORMATIONAL AND EDUCATIONAL PURPOSES. CONTACT A FINANCIAL PROFESSIONAL BEFORE MAKING ANY FINANCIAL DECISIONS. FOLLOWTHEMONEY.COM, AND ITS SUBSIDIARIES SHALL NOT BE HELD LIABLE FOR ANY INVESTMENT DECISIONS EMPLOYED BY OUR MEMBERS.

AS ALWAYS, INVEST AND TRADE AT YOUR OWN RISK!